Hepatocellular carcinoma (HCC) is a common cause of cancer-related deaths worldwide.
Unlike other types of cancer, HCC can be treated with locoregional treatments (LRTs) such …

Locoregional therapies (LRTs) including radiofrequency ablation, surgical resection, and
TACE, play a pivotal role in the treatment of early stage/locally advanced hepatocellular …

Hepatocellular carcinoma (HCC) is associated with a highly heterogeneous immune
environment that produces an immune response to various locoregional treatments (LRTs) …

Background Immunotherapy represents a promising option for treatment of hepatocellular
carcinoma (HCC) in cirrhotic patients but its efficacy is currently inconsistent and …

Hepatocellular carcinoma (HCC) is a frequent cancer with a high mortality. For early stage
cancer there are potentially curative treatments including local ablation, resection and liver …

Immunotherapy has remarkably revolutionized the management of advanced HCC and
prompted clinical trials, with therapeutic agents being used to selectively target immune cells …

Immunomodulation for hepatocellular carcinoma therapy: curre... : Current Opinion in Oncology
Immunomodulation for hepatocellular carcinoma therapy: current challenges : Current Opinion …

The management of hepatocellular carcinoma (HCC) is challenging because most patients
have underlying cirrhosis, and the treatment provides, historically, a limited impact on the …

With mortality rates of liver cancer doubling in the last 20 years, this disease is on the rise
and has become the fifth most common cancer in men and the seventh most common …

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths
worldwide and is increasing in incidence. Local ablative therapy plays a leading role in HCC …